SUMMARY Sensitive, precise, and rapid methods for the measurement of alcohol dehydrogenase (ADH) and glutamate dehydrogenase (GDH) were developed on the Cobas Bio centrifugal analyser. The optimal pH for ADH in caucasians was 9-8. Non-linearity of ADH enzyme activity was observed when samples were diluted in saline; linearity was restored when inactivated serum was used as diluent. ADH was shown to be a sensitive index of liver anoxia due to cardiorespiratory disturbance (clinical sensitivity 90%) and generalised anoxia. GDH exhibited sensitivity equal to that of alanine aminotransferase (ALT) but was inferior to gamma-glutamyltransferase (GGT) in the detection of specific liver disease. Both ADH and GDH were sensitive indicators of alcoholic liver disease.
Alcohol dehydrogenase (ADH, EC 1.1.1.1) is a cytoplasmic liver enzyme located predominantly in the centrilobular region of the liver (zone 3 of the hepatic acinus); glutamate dehydrogenase (GDH, EC 1.4.1.2) is predominantly a liver enzyme found in mitochondria. Until recently critical assessment of the diagnostic potential of these two enzymes was limited by (i) their very low activity in normal human serum and (ii) the lack of sensitive spectrophotometric assay techniques to measure their activities.
Several recent reports document differing and often conflicting clinical uses for these enzymes. Fujisawa et al stated that ADH is a sensitive marker for chronic hepatitis and chronic aggressive hepatitis, but not for obstructive jaundice. Khayrollah et al' concluded that ADH is a sensitive indicator for assessing hepatotoxicity due to drugs, hepatocellular damage, infection, inflammation and malignancy. More recently, Kato et al34 stated that ADH activity may be raised in patients with hepatic centrilobular damage. Glutamate dehydrogenase was shown by Jung et al to be of similar diagnostic sensitivity to mitochondrial aspartate aminotransferase (AST, EC 2.6.1.1) in chronic pathological liver states. Schellenberg et a!6
Accepted for publication 4 March 1987 stated that the place of GDH in the laboratory was in the detection of heavy drinkers. Levy7 concluded that GDH was useful as a cancer marker in hepatic metastases, while Kim et al8 showed that, although GDH was as sensitive and specific as serum alkaline phosphatase activity (AP, EC 3.1.3.1) in the detection of hepatic metastases, it was inferior to gammaglutamyltransferase (GGT, EC 2.3.2.2) and 5'-nucleotidase (5'NT, EC 3.1.3.5).
This paper describes the development of sensitive routine methods for the measurement of GDH and ADH using a centrifugal analyser. For GDH, a manual kit procedure was adapted for use with the centrifugal analyser. A method for ADH using centrifugal analysis has recently been reported by Kato' in Japan. As racial differences in ADH activity, caused by isoenzyme heterogeneity have been documented,'
we modified this method and optimised reaction conditions for a caucasian population.
The clinical use of these enzymes was examined in several selected patient groups, with particular attention being focused on those conditions which may, as a result of primary cardiorespiratory disturbance, lead to centrilobular necrosis. Alanine aminotransferase (ALT, EC 2.6.1.2) and gammaglutamyltransferase activities were measured concurrently for comparative purposes. Precision studies Three patients' sera with low, moderate, and raised GDH activity (8, 45 , and 160 U/l, respectively) were selected for both intrarun and interrun precision studies of the assay. Samples to be analysed for interrun precision were stored at -70°C. Table 2 summarises the results and shows that both assays are precise, with coefficients of variation at all levels of 5-1% or less.
Linearity Serial dilutions were prepared from a patient sample with GDH activity of 750 U/I and used to assess the linearity of each method. The assay was linear up to 500 U/1.
Reference range Serum from 100 apparently healthy subjects, all of whom had normal ALT activities, was used to derive a reference range for GDH. Data were processed using non-parametric statistics. The reference range for GDH was calculated as 0-5 U/1. Stability A trial to assess GDH stability was conducted. Three samples with low (5 U/1), moderate (50 U/1), and high (150 U/l) GDH activity were stored at 40C, -200C, and -70°C for one week. All samples, independent of their activity, were stable over the week when stored at -70°C. Results obtained for storage at 4°C and -20°C were similar and showed that for the low sample GDH activity was stable for 48 hours, while for the moderate and high samples, on average, 5% activity was lost each day, that is, after one week, there was nearly a 40% reduction in initial activity.
MODIFICATION AND OPTIMISATION OF ADH ASSAY ON COBAS BIO
Determination ofpH optimum In a study of Japanese subjets Kato determined the pH optimum for ADH, using glycine-NaOH buffer, to be 9 03; however, the author qualified this finding by stating that the pH optimum would need to be redetermined for caucasians.
Using the assay conditions of Kato (table 1) depletion occurred after 360 seconds with ADH samples greater than 250 U/l, a reading interval of 180 seconds (18 readings at 10 second intervals) was selected for our assay system. Total analysis time was therefore five minutes. Activities were calculated using linear regression (printout mode 2). Table I lists final instrument settings for the ADH assay.
Linearity
Two patient samples, with activities of 400 and 35 U/l, respectively, were each diluted serially in saline and analysed on the Cobas Bio. Non-linearity was observed with both samples and was more exaggerated in the dilution of the low sample. A similar finding has been reported by the authors12 in studies with intestinal alkaline phosphatase, when a sample of high activity was diluted in saline. The two ADH samples were serially diluted in inactivated serum (prepared by heating serum at 65°C for 10 minutes). In contrast to the results found using saline as diluent, linearity was observed in both samples using the ?genase and alcohol dehydrogenase serum based diluent (fig 3) . A repeat of the linearity experiment using a further patient sample (total activity 480 U/1) diluted with inactivated serum confirmed that the linear range of the ADH assay was 0-250 U/l. Shephard, Penberthy, Berry Precision studies Intrarun and interrun precision data were obtained using different patient sera with low, moderate, and raised activities of ADH. Table 3 summarises the results. Precision recorded using this assay system was superior to that documented by Kato.3 Reference range From a population of 70 apparently healthy subjects, a reference range of 0-7 U/I for ADH was calculated using non-parametric statistics. This compares favourably with the range of 0-5 U/I determined by Kato group were diagnosed as having obstructive jaundice or cirrhosis (n = 5), viral hepatitis (n = 1), alcoholic liver disease (n = 7) and carcinoma (n = 7). Fig 4 shows the activities of each enzyme found in these patients. The clinical sensitivity-that is, the number of abnormal test results in those patients with disease-of each enzyme for each group and selected subgroups (those with n > 5) was also documented (table 4) . Table 4 shows that ADH is a highly sensitive marker for liver anoxia and resultant centrilobular damage caused by cardiorespiratory disturbance (in particular congestive cardiac failure). This finding confirms and extends the preliminary work of Kato.4 Our data show that ADH is also a sensitive indicator of generalised anoxia. In terms of specific liver disease, and in particular, carcinoma of the liver, GGT was found to be superior to the other enzymes tested. GDH does not seem to have a role in detecting liver anoxia, but is at least equivalent in sensitivity to ALT as a marker for liver disease. In many cases of liver disease, an increase in ALT activity was paralleled by an increase in GDH, but the relative increase in activity-that is, the number of times greater than the top of the reference range-was far greater with GDH than with ALT. All enzymes were equally sensitive in detecting alcoholic liver disease.
Conclusion
We have developed and adapted methods for the determination of serum alcohol dehydrogenase and glutamate dehydrogenase for use with a centrifugal analyser. These enzymes were shown in a clinical study to be relatively useful markers for detection of a variety of specific liver disease states, though they were not more clinically sensitive than conventional liver enzymes such as alanine aminotransferase and, particularly, gamma-glutamyltransferase. Our findings suggest, however, that alcohol dehydrogenase may have considerable diagnostic potential in the detection of generalised anoxia and, in particular, anoxic damage to the liver caused by cardiorespiratory disorders.
